Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Colorectal Neoplasm, Hepatic Neoplasm
Interventions
DCE-MRI
Other
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Pancreatic Cancer
Interventions
Abraxane
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Conditions
Pancreatic Neoplasm
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
14 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Cancer, Breast Cancer, Colon Cancer, Cervical Cancer, Uterine Cancer, Ovarian Cancer
Interventions
Very low carbohydrate diet (approximately 20 grams per day)
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Colon Cancer, Rectal Cancer
Interventions
MK-2206
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Epidemiologic Study of Hepatocellular Carcinoma in the US

NCT02358070
Conditions
Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
35 Years to 84 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Not listed No phase listed Observational Accepts healthy volunteers

A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark

NCT00902902
Conditions
Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Peking Union Medical College Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Colorectal Carcinoma
Interventions
Best Practice, Medical Chart Review, Online Mindfulness Meditation, Survey Administration
Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Cancer of Liver
Interventions
Capecitabine (Xeloda)
Drug
Lead sponsor
James A. Haley Veterans Administration Hospital
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Pancreas Cancer
Interventions
Standard Informed Consent, Multimedia Video - Based Informed Consent
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Colon Cancer, Diverticulitis, Colorectal Polyps, Crohn's Disease, Ulcerative Colitis, Rectal Cancer
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
14 Years to 95 Years
Enrollment
200,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
4
States / cities
Chicago, Illinois • Indianapolis, Indiana • Minneapolis, Minnesota + 1 more
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Feasibility of ActivSightTM in Human

NCT04633512
Conditions
Acute Cholecystitis, Colorectal Cancer, Diverticulitis, Colonic, Obesity, Morbid, Inflammatory Bowel Diseases
Interventions
ActivSight
Device
Lead sponsor
Activ Surgical
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Houston, Texas • Sugar Land, Texas
Conditions
Pancreatic Cancer, Gastric Cancer, Duodenum Cancer, Bile Duct Cancer
Interventions
irinotecan, radiation therapy
Drug · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Neoplasms
Interventions
ADH300004
Drug
Lead sponsor
Adherex Technologies, Inc.
Industry
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer
Interventions
Laboratory Biomarker Analysis, Regorafenib
Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
3
States / cities
Buffalo, New York • Rocherster, New York • Columbus, Ohio
Conditions
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions
Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
171
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more
Active, not recruiting Phase 1 Interventional

First in Human Study of AZD9592 in Solid Tumors

NCT05647122
Conditions
Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
Interventions
AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • North Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Conditions
Colorectal Carcinoma
Interventions
Biospecimen Collection, Survey Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Terminated Not applicable Interventional Results available

PET/MR for Rectal Cancer Treatment Monitoring and Surveillance

NCT04150705
Conditions
Rectal Cancer, Cancer of the Rectum
Interventions
FDG PET/MRI
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions
Intensity Modulated Radiation Therapy, Carboplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel
Radiation · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma
Interventions
HFB301001
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Conditions
Adenocarcinoma, Neuroendocrine Tumors, Hepatocellular Carcinoma, Cholangiocarcinoma, Malignant Lymphoma, Metastasis, Chronic Pancreatitis, Autoimmune Pancreatitis
Interventions
EchoTip AcuCore
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Orange, California • Denver, Colorado • Gainesville, Florida + 4 more
Terminated Phase 1 Interventional Results available

A Study of LY3435151 in Participants With Solid Tumors

NCT04099277
Conditions
Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma
Interventions
LY3435151, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas